SILO PHARMA, INC. Amortization of Debt Discount (Premium)
SILO PHARMA, INC. (SILO) reported Amortization of Debt Discount (Premium) of $268.13 thousand for the 12-month period ending 2020-12-31, per its 10-K/A filed 2021-05-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2021-05-17
- SILO PHARMA, INC. amortization of debt discount (premium) for the quarter ending 2020-12-31 was $82.50K.
- SILO PHARMA, INC. amortization of debt discount (premium) for the quarter ending 2020-09-30 was $268.13K.
- SILO PHARMA, INC. amortization of debt discount (premium) for the quarter ending 2020-06-30 was $268.13K.
- SILO PHARMA, INC. amortization of debt discount (premium) for the quarter ending 2020-03-31 was $82.50K.
- SILO PHARMA, INC. amortization of debt discount (premium) for fiscal 2020 was $268.13K, a 333.33% increase from fiscal 2019.
- SILO PHARMA, INC. amortization of debt discount (premium) for fiscal 2019 was $61.88K.
- SILO PHARMA, INC. amortization of debt discount (premium) for fiscal 2018 was $0.00.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|
| 2020-12-31 | $82.50K derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-17 | $350.63K derived: sum of 2 quarters · filed 2021-05-17 | $618.75K derived: sum of 3 quarters · filed 2021-05-17 | $268.13K 10-K/A · filed 2021-05-17 |
| 2020-09-30 | $268.13K 10-Q · filed 2020-11-05 | $536.25K derived: sum of 2 quarters · filed 2020-11-05 | $185.63K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $268.13K 10-Q · filed 2020-08-14 | $185.63K 10-Q · filed 2020-08-14 | ||
| 2020-03-31 | $82.50K 10-Q · filed 2020-05-12 | |||
| 2019-12-31 | $61.88K 10-K/A · filed 2021-05-17 | |||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-12 | |||
| 2018-12-31 | $0.00 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |